Erratum to: “Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study” [Haematologica. 2025; 110(4):985-989. DOI: 10.3324/haematol.2024.286082]

In the original article “Donor cytomegalovirus serology impacts overall survival in children receiving first unrelated hematopoietic stem cell transplant for acute leukemia: European Society of Bone Marrow Transplantation Pediatric Diseases Working Party Study”,1 the following errors were noticed: (i) the color-coding of D+ and D- donors for R- patients were inverted and the correct Figure 1 with its legend is shown below; (ii) the name of the 17th author was misspelled and the affiliation was incorrect. The correct spelling is “Jochen Buechner” and the correct affliation is “Oslo University Hospital, Department of Pediatric Hematology and Oncology, Oslo, Norway”. (Figure Presented.) Figure 1. Overall survival in relation to patient and donor cytomegalovirus serology. (A) Kaplan-Meier estimates of overall survival (OS) in seropositive recipients (R+) undergoing matched unrelated hematopoietic stem cell transplantation (HSCT) from a seronegative (D- in red) versus seropositive (D+ in black) donors. (B) Kaplan-Meier estimates of OS in seronegative recipients (R-) undergoing matched unrelated HSCT from a seronegative (D- in red) versus seropositive (D+ in black) donors. Shown are adjusted hazard ratios (HR) with 95 % confidence intervals in round brackets.